Abstracts tagged "osteoarthritis and pain"

Abstract Number: 1364 • 2018 ACR/ARHP Annual Meeting
Treatment of Knee Osteoarthritis with SM04690 Improved WOMAC A1 “Pain on Walking” – Results from a 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor
Jeyanesh Tambiah¹, Sarah Kennedy¹, Heli Ghandehari¹, Christopher Swearingen¹ and Marc C. Hochberg², ¹Samumed, LLC, San Diego, CA, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Knee osteoarthritis (OA) is characterized by pain, functional limitation, and physical disability due to articular cartilage degradation and bone remodeling. Wnt signaling is involved…
Abstract Number: 1377 • 2018 ACR/ARHP Annual Meeting
Knee Osteoarthritis Symptom Duration Is Associated with Conditioned Pain Modulation and Vibration Perception Threshold Impairment
Kharma C. Foucher¹, Samuel Chmell² and Carol Courtney³, ¹Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, ²Orthopedic Surgery, University of Illinois at Chicago, Chicago, IL, ³Physical Therapy, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Impaired descending pain inhibition has been observed in people with knee OA and may be associated with development of chronic pain as well as…
Abstract Number: 425 • 2018 ACR/ARHP Annual Meeting
Efficacy, Safety, and Tolerability of ONO-4474, an Orally Available Pan-Tropomyosin Receptor Kinase Inhibitor, in Japanese Patients with Moderate-to-Severe Osteoarthritis of the Knee: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Comparative Study
Naoki Ishiguro¹, Shusuke Oyama², Ryunosuke Higashi³ and Kunio Yanagida⁴, ¹Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Data Science, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ³Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ⁴Translational Science, Translational Medicine Center, Ono Pharmaceutical Co., Ltd, Osaka, Japan
Background/Purpose: ONO-4474 is an orally available, peripheral-specific, pan-tropomyosin receptor kinase (pan-Trk) inhibitor currently under development for treatment of musculoskeletal pain in OA patients. This study…
Abstract Number: 1920 • 2018 ACR/ARHP Annual Meeting
Is There Objective Evidence of Neuropathy in Knee Osteoarthritis Based on Clinical Evaluation?
Priyanka Ballal¹, Joachim Scholz², Laura Frey-Law³, Na Wang¹, Michael C. Nevitt⁴, Cora E. Lewis⁵ and Tuhina Neogi⁶, ¹Boston University School of Medicine, Boston, MA, ²Departments of Anesthesiology and Pharmacology, Columbia University Medical Center, New York, NY, ³University of Iowa, Iowa City, IA, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵University of Alabama Birmingham, Birmingham, AL, ⁶Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Self-reported descriptors of pain in knee osteoarthritis (OA) such as burning and stabbing pain are suggestive of a neuropathic component of pain beyond that…
Abstract Number: 426 • 2018 ACR/ARHP Annual Meeting
The Association of Dietary Patterns with Knee Symptoms and MRI Detected Structures in Patients with Knee Osteoarthritis (OA)
Shuang Zheng¹, Feitong Wu¹, Flavia Cicuttini², Anita E Wluka², Dawn Aitken¹, Tania Winzeberg^1,3, Leigh Blizzard¹, Graeme Jones⁴ and Changhai Ding^1,5, ¹Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ²Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, ³Faculty of Health, University of Tasmania, Hobart, Australia, ⁴Menzies Institute for Medical Research, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ⁵Clinical Research Centre, Zhujiang Hospital, Southern Medical University, Guangzhou, China
The association of dietary patterns with knee symptoms and MRI detected structures in patients with knee osteoarthritis (OA)Abstract Background/Purpose: This study aimed to examine the…
Abstract Number: 1994 • 2018 ACR/ARHP Annual Meeting
Osteoarthritis Severity Is Reduced By Intra-Articular Administration of Hydrogen Sulfide
Elena F. Burguera^1,2, Angela Vela-Anero³, Carlos Vaamonde-Garcia³, Tamara Hermida-Gómez^1,2, Purificacion Filgueira-Fernandez^1,2, Lucía Gato-Calvo², Rosa Meijide-Failde⁴ and Francisco J Blanco⁵, ¹CIBER-BBN, Madrid, Spain, ²Unidad de Medicina Regenerativa, Grupo de Investigación en Reumatología, Agrupación Estratégica CICA-INIBIC, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade de A Coruña (UDC), A Coruña, Spain, ³Department of Physiotherapy, Medicine and Biological sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain, ⁴Department of Physiotherapy, Medicine and Biological Sciences, Tissue Engineering and Regenerative Medicine group (University of A Coruña), A Coruña, Spain, ⁵Grupo de Investigación en Reumatología, Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain
Background/Purpose: Hydrogen sulphide (H2S) is recognized as a therapeutic target in osteoarthritis (OA). Exogenous supplementation with synthetic salts in in vitro models of OA has…
Abstract Number: 62 • 2017 ACR/ARHP Annual Meeting
Convergence of Joint Repair and Pain Pathways Via Nerve Growth Factor and p75 Expressing Mesenchymal Stem Cells in Established Osteoarthritis
Thomas Baboolal¹, Sumaiya Al Hinai², Elena Jones², Jill Reckless³, Martyn Foster⁴, Rachel Doyle⁵, Kerry af Forselles⁴, Simon Westbrook⁴ and Dennis McGonagle², ¹PhD, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Rxcelerate Ltd, Cambridge, United Kingdom, ⁴Levicept Ltd, Ramsgate, United Kingdom, ⁵Tetrad Discovery Ltd, Ramsgate, United Kingdom
Background/Purpose: Nerve growth factor (NGF) is a key regulator of pain and anti-NGF therapy reduces osteoarthritis (OA) associated pain. However, anti-NGF therapy is associated with…
Abstract Number: 1193 • 2017 ACR/ARHP Annual Meeting
A Randomized, Placebo-Controlled, Double-Blind, Phase II Clinical Trial of the First-in-Class Imidazoline-2 Receptor Ligand CR4056 in Pain from Knee Osteoarthritis and Disease Phenotypes
Lucio C. Rovati¹, Nadia Brambilla¹, Tomasz Blicharski², Nicholas J Probert³, Cristina Vitalini¹, Giampaolo Giacovelli¹, Federica Girolami¹ and Massimo D'Amato¹, ¹Clinical Research Department, Rottapharm Biotech, Monza, Italy, ²Lubelskie Centrum Diagnostyczne, Świdnik, Poland, ³MAC Clinical Research, Manchester, United Kingdom
Background/Purpose: CR4056 is a novel imidazoline-2 receptor (I2R) ligand endowed with potent analgesic activities in several and diverse animal models of nociceptive and neuropathic pain,…
Abstract Number: 1195 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tanezumab in Patients with Knee or Hip Osteoarthritis (NCT01089725)
Charles A. Birbara¹, Eugene J. Dabezies², Aimee M. Burr³, Robert J. Fountaine⁴, Michael D. Smith³, Mark T. Brown³, Christine R. West³, Rosalinda H. Arends³ and Kenneth M. Verburg³, ¹University of Massachusetts Medical School, Worcester, MA, ²Pensacola Research Consultants, Pensacola, FL, ³Pfizer, Inc., Groton, CT, ⁴Pfizer, Inc., Grotoon, CT
Background/Purpose : Tanezumab (TNZ) is a monoclonal antibody that inhibits nerve growth factor and reduces hip or knee osteoarthritis (OA) pain. A placebo-controlled phase 3…
Abstract Number: 2183 • 2017 ACR/ARHP Annual Meeting
Two-Year Changes in Knee Osteoarthritis Symptoms: Comparing Clinical Relevance of Patient-Reported Outcomes By Anchoring to Knee Replacement
C. Kent Kwoh¹, Hans Guehring², Erin Ashbeck³, Michael J Hannon⁴ and Aida Aydemir⁵, ¹University of Arizona Arthritis Center, Tuscan, AZ, ²Merck KGaA, Darmstadt, Germany, ³The University of Arizona Arthritis Center, Tucson, AZ, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA, ⁵EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA
Background/Purpose: Randomized controlled trials (RCTs) of interventions for knee OA (KOA) may include a patient-reported outcome (PRO) measure as a primary endpoint. Several measures of…
Abstract Number: 2186 • 2017 ACR/ARHP Annual Meeting
The Role of Hip Injury in Pain Exacerbation in Hip Osteoarthritis: an Internet-Based Case-Crossover Study
Kai Fu¹, Joanna Makovey², Ben Metcalf³, Kim Bennell³, Yuqing Zhang⁴, Rebecca Asher⁵, Sarah Meneses², Leticia Deveza² and David Hunter², ¹Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Syndey, Australia, ²Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ³Centre for Health, Exercise and Sports Medicine, Department of Physiotherapy, University of Melbourne, Melbourne, Australia, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
Background/Purpose: Pain is the main symptom in hip osteoarthritis (OA) and many patients experience recurrent pain exacerbations. The purpose of this study is to evaluate…
Abstract Number: 2204 • 2017 ACR/ARHP Annual Meeting
Neuropathic Pain in Patients with Knee Osteoarthritis and Related Factors: A Multicenter Longitudinal Study-Preliminary Report
Ece Kaptanoglu¹, Ozlem Şahin², Tiraje Tuncer³, Sami Hizmetli¹, Lale Altan⁴, Figen Ayhan⁵, Ajda Bal⁶, Meral Bilgilisoy⁷, Gulnur Bozbas⁸, Lale Cerrahoglu⁹, Remzi Cevik¹⁰, Tuncay Duruoz¹¹, Deniz Dulgeroglu⁶, Gulcan Gurer¹², Savas Gursoy¹³, Simin Hepguler¹⁴, Cahit Kacar¹⁵, Taciser Kaya¹⁶, Meltem Melikoglu¹⁷, Kemal Nas¹⁸, Suheda Ozcakir¹⁹, Senay Ozdolap²⁰, merih Saridogan²¹, Selda Sarikaya²⁰, Dilsad Sindel²², Omer F Şendur⁸, Canan Tikiz²³ and Hatice Ugurlu²⁴, ¹Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Cumhuriyet University School of Medicine, Sivas, Turkey, ²Department of Physical Medicine and Rehabilitation, Cumhuriyet University School of Medicine, Sivas, Turkey, ³Department of Physical Medicine and Rehabilitation, Akdeniz University School of Medicine, Antalya, Turkey, ⁴Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Uludag University School of Medicine, Bursa, Turkey, ⁵Department of Physical Medicine and Rehabilitation, University of Health Ankara Training and Research Hospital, Ankara, Turkey, ⁶Department of Physical Medicine and Rehabilitation, University of Health Sciences Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey, ⁷Department of Physical Medicine and Rehabilitation, University of Health Sciences Antalya Training and Research Hospital, Antalya, Turkey, ⁸Department of Physical Medicine and Rehabilitation, Adnan Menderes University School of Medicine, Aydin, Turkey, ⁹Department of Physical Medicine and Rehabilitation, Celal Bayar University School of Medicine, Manisa, Turkey, ¹⁰Department of Physical Medicine and Rehabilitation, Dicle University School of Medicine, Diyarbakir, Turkey, ¹¹Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ¹²Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Adnan Menderes University School of Medicine, Aydin, Turkey, ¹³Department of Physical Medicine and Rehabilitation, Gaziantep University School of Medicine, Gaziantep, Turkey, ¹⁴Department of Physical Medicine and Rehabilitation, Ege University School of Medicine, Izmir, Turkey, ¹⁵Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Akdeniz University School of Medicine, Antalya, Turkey, ¹⁶Department of Physical Medicine and Rehabilitation, University of Health Sciences İzmir Bozyaka Training and Research Hospital, Izmir, Turkey, ¹⁷Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ataturk University School of Medicine, Erzurum, Turkey, ¹⁸Department of Physical Medicine and Rehabilitation, Sakarya University School of Medicine, Sakarya, Turkey, ¹⁹Department of Physical Medicine and Rehabilitation, Uludag University School of Medicine, Bursa, Turkey, ²⁰Department of Physical Medicine and Rehabilitation, Bulent Ecevit University School of Medicine, Zonguldak, Turkey, ²¹Department of Physical Medicine and Rehabilitation, Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey, ²²Department of Physical Medicine and Rehabilitation, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ²³Celal Bayar University School of Medicine, Manisa, Turkey, ²⁴Department of Physical Medicine and Rehabilitation, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey
Background/Purpose: Neuropathic pain (NP) was accused for increased pain and reduced functional capacity in knee osteoarthritis (KO). Here we aimed to find out the prevalence…
Abstract Number: 2232 • 2017 ACR/ARHP Annual Meeting
A Role for CCR2 in Chronic Behavioral and Neuroimmune Changes in the DMM Model of Osteoarthritis
Phuong Tran¹, Shingo Ishihara², Rachel E. Miller³, Richard J. Miller⁴ and Anne-Marie Malfait¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Biochemistry, Rush University Medical Center, Chicago, IL, ⁴Pharmacology/Medical Humanities and Bioethics, Northwestern University, Chicago, IL
Background/Purpose: The aim of this study was to explore pain-related behaviors and associated cellular changes in the pain pathway in experimental osteoarthritis (OA) induced by…
Abstract Number: 2236 • 2017 ACR/ARHP Annual Meeting
Neuropathic Pain in End-Stage Hip and Knee Osteoarthritis: Differences between Men and Women and Differential Associations with Pain at Rest and Pain on Activity
J. Denise Power¹, Anthony V. Perruccio¹, Rajiv Gandhi¹, Christian Veillette¹, J. Roderick Davey¹, Khalid Syed¹, Nizar Mahomed¹ and Y. Raja Rampersaud², ¹Arthritis Program, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Arthritis Program, Krembil Research Institute, University Health Network, Torotno, ON, Canada
Background/Purpose: There is increasing support in the literature for a neuropathic component to OA pain. Our primary objective was to determine whether pain at rest…
Abstract Number: 2852 • 2017 ACR/ARHP Annual Meeting
Widespread Pain Prior to Total Knee Replacement (TKR) Is Associated with Increased Risk of No Clinical Improvement in Pain Among Women
Ernest Vina¹, Di Ran², Erin L. Ashbeck² and C. Kent Kwoh³, ¹Rheumatology, University of Arizona, Tucson, AZ, ²The University of Arizona Arthritis Center, Tucson, AZ, ³University of Arizona, Tucson, AZ
Background/Purpose: Up to 47% of individuals may not have clinically significant improvement following joint replacement surgery. Evidence also suggests that women are less likely to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].